Von Willebrand Disease (vWD) Treatment Is Tailored to the Subtype of the Disease
Von Willebrand disease treatment focuses on preventing bleeding episodes, normally by using medication. It is a lifelong bleeding disorder caused by low levels of protein clots in the blood or a deficiency of von Willebrand factor, which binds a key clotting protein, factor VIII, and platelets in blood vessel walls. The three forms of Von Willebrand disease are acquired, hereditary, and platelet or pseudo type. The three types of hereditary vWD are type 1 vWD, type 2 vWD, and type 3 vWD. Platelet type vWD is also an inherited condition.
It may develop later in life, but in rare cases, it is often inherited. Symptoms may include excessive bleeding from a cut, increased menstrual flow, bleeding from the gums, and recurrent and prolonged nosebleeds. Desmopressin, an antidiuretic hormone, is a common medication used for the Von Willebrand disease treatment. It triggers the release of Willebrand factor into the plasma and can increase factor VIII levels. Moreover, several major private sector and government organizations are forging strategic alliances to increase the efficacy and success rate of existing, as well as upcoming treatments.
Moreover, research and development activities are expected to increase the overall potential for the von Willebrand disease treatment, and pave the way for new therapies and diagnostics frameworks. Currently, new therapies address the primary deficiency of vWD. Extensive research is underway to evaluate the efficacy of new treatments in different clinical situations. The demand for Von Willebrand disease treatment is increasing with the increasing demand for progressive treatment options, an increase in patient assistance programs, and increasing adoption of new technologies, especially in North America.
For instance, Von Willebrand disease is the most common bleeding disorder, affecting up to 1% of the U.S. population, according to the National Hemophilia Foundation.
Comments
Post a Comment